Trastuzumab Deruxtecan in HER2Low Advanced Breast Cancer NEJM

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=Phg39MG4XzE

Patients with HER2-low breast cancer have limited targeted treatment options for progressing disease after primary therapy. An antibody–drug conjugate has shown efficacy in early trials. • New research findings are summarized in a short video. • To see the full article, follow this link: https://nej.md/3aCIH6d

#############################

New on site